IFAT

IFAT
Name	IFAT
Purpose	Antibody detection
Specimen	Serum, plasma

IFAT

IFAT is an immunological laboratory assay used to detect specific antibodies in patient serum or plasma through fluorescent labeling of antigen–antibody complexes. The test is applied in diagnostics for a range of infectious and autoimmune conditions and is performed in clinical and research laboratories affiliated with hospitals such as Mayo Clinic, Johns Hopkins Hospital, and public health institutions including the Centers for Disease Control and Prevention and the World Health Organization. Protocol variations and interpretation criteria are governed by standards from organizations like the Clinical and Laboratory Standards Institute.

Overview

IFAT combines principles first described by researchers at institutions such as Albert Einstein College of Medicine and laboratories influenced by methods from Paul Ehrlich-era histochemistry to provide visually assessed fluorescence using microscopes manufactured by firms like Leica Microsystems and Zeiss. The assay relies on antigens derived from pathogens or cultured cells sourced from repositories such as the American Type Culture Collection and employs secondary antibodies conjugated to fluorophores developed by companies like Thermo Fisher Scientific and Abcam. Common clinical applications link IFAT to diagnoses associated with organisms including Toxoplasma gondii, Leishmania, Trypanosoma cruzi, and autoantibody patterns relevant to diseases catalogued by centers such as National Institutes of Health.

History and Development

The fluorescent antibody technique evolved from early immunofluorescence work performed at laboratories such as Pasteur Institute and expanded through mid-20th-century innovations at universities like Harvard University and University of Cambridge. Adaptations for serology mirrored advances in fluorescence microscopy by developers like Ernst Ruska and in fluorochrome chemistry associated with researchers at Imperial College London. Major public health outbreaks investigated by agencies including the Public Health England and the Pan American Health Organization prompted standardization efforts for IFAT protocols. Commercial kit development involved biotechnology firms such as Roche and Siemens Healthineers, which produced standardized slides and conjugates to support clinical adoption.

Indications and Clinical Use

IFAT is indicated for detection of pathogen-specific IgG or IgM in contexts managed by institutions such as Centers for Disease Control and Prevention reference laboratories and hospital infectious disease services at Massachusetts General Hospital. Clinical indications include confirmation of parasitic infections referenced in guidelines by organizations like the American Society of Tropical Medicine and Hygiene and assessment of autoimmune markers relevant to specialties at Cleveland Clinic and rheumatology centers such as Hospital for Special Surgery. IFAT is used in surveillance programs coordinated by public health agencies including the European Centre for Disease Prevention and Control and in research projects at universities like University of Oxford investigating seroprevalence after outbreaks documented by United Nations health initiatives.

Procedure and Methodology

Typical IFAT workflow begins with antigen preparation using cultured organisms from repositories like the American Type Culture Collection or cell lines maintained at institutions such as Dana-Farber Cancer Institute. Patient serum is incubated on antigen-coated slides and washed under conditions optimized in protocols from the Clinical and Laboratory Standards Institute. Secondary antibodies labeled with fluorophores like FITC or Alexa Fluor, produced by suppliers including Thermo Fisher Scientific and Bio-Rad Laboratories, are applied. Reading is performed using fluorescence microscopes from Zeiss or Leica and interpreted by trained personnel credentialed through programs at organizations such as the American Society for Clinical Pathology. Quality control employs positive and negative controls traceable to standards used by agencies like the National Institute of Standards and Technology.

Interpretation and Limitations

Interpretation requires correlation with clinical findings documented by treating centers such as Johns Hopkins Hospital and comparison with serologic thresholds recommended by bodies like the World Health Organization. Fluorescence intensity and titration endpoint provide semiquantitative results, but operator-dependent variability at laboratories including community hospital services can affect reproducibility. Cross-reactivity has been reported among related pathogens documented in literature from Centers for Disease Control and Prevention investigations, and false negatives can occur in early infection windows described in studies from University of California, San Francisco. Antigenic variation in organisms such as Leishmania or immune suppression in patients at transplant centers like Stanford Health Care further limit sensitivity and specificity.

Comparison with Other Diagnostic Tests

Compared with enzyme-linked immunosorbent assay assays used in reference labs at Quest Diagnostics and rapid diagnostic tests distributed by manufacturers such as Abbott Laboratories, IFAT offers advantages in visualizing cellular or whole-organism antigen patterns, similar to indirect hemagglutination tests used historically at agencies like Centers for Disease Control and Prevention. Molecular methods including polymerase chain reaction assays developed at institutions such as Broad Institute provide direct detection of nucleic acids and often greater sensitivity in early infection, while IFAT remains useful for antibody detection and seroconversion studies employed in epidemiologic research at universities such as Columbia University. Neutralization assays conducted at vaccine centers like Gavi, the Vaccine Alliance complement IFAT by measuring functional antibody activity, whereas immunoassays automated on platforms from Roche and Siemens Healthineers offer higher throughput for screening programs coordinated by public health institutes like Public Health England.

Category:Immunologic tests